A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...
Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers. A ...
NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...
Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results